Clinical Trials NCT06869785

Active, Not RecruitingPhase 3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsored by Novartis Pharmaceuticals

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
196
Target enrollment
24
U.S. states
Mar 2025
Start date
Mar 2030
Expected completion
Interventions / Treatments
Ofatumumab approved doseOfatumumab new dose
Conditions studied
Relapsing Multiple Sclerosis (RMS)
Where this trial is running (61 sites)
Florida18 sites
Altamonte Springs · Boca Raton · Boca Raton · +15 more
California6 sites
Berkeley · Fullerton · Irvine · +3 more
Arizona3 sites
Phoenix · Phoenix · Phoenix
Louisiana3 sites
Alexandria · New Orleans · New Orleans
Ohio3 sites
Centerville · Cincinnati · Columbus
Tennessee3 sites
Cordova · Knoxville · Knoxville
Kansas2 sites
Kansas City · Roeland Park
Maryland2 sites
Bethesda · Lutherville
Michigan2 sites
Detroit · Rochester Hills
New York2 sites
Patchogue · Port Jefferson
Texas2 sites
Dallas · Plano
Virginia2 sites
Arlington · Virginia Beach
Washington2 sites
Seattle · Tacoma
Alabama1 site
Birmingham
Colorado1 site
Aurora
Washington D.C.
Georgia1 site
Atlanta
Indiana1 site
Indianapolis
Missouri1 site
St Louis
Nevada1 site
Las Vegas
Hackensack
Raleigh
Philadelphia
Wisconsin1 site
Milwaukee
Participating MS centers on MS Buddy (33)
True North Neurology
Port Jefferson Station, NY
Advent Neurology Clinic
Roeland Park, KS
Neurology of Central Florida
Altamonte Springs, FL
MS centers in Florida

Compare treatment centers near a trial site — patient experience, providers, and care ratings.

View Florida centers
More Phase 3 trials
Browse all Phase 3 MS trials

Check out the MS Buddy App

Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.

Download on the App StoreGet it on Google Play